Abstract:<h3> Background</h3><p>Influenza is a highly contagious disease with global annual outbreaks of 3–5 million severe cases and 0.25 to 0.5 million deaths. The risk is greater in pregnant women that results in high morbidity and mortality.</p><h3> Objective</h3><p>The objective of this study was to see the efficacy of influenza vaccine on pregnant women and their newborn upto six months.</p><h3> Method</h3><p>This was a retrospective study (January 2016–March 2018). Records of 346 pregnant women were included in this study (vaccinated: 288; unvaccinated: 58). Women and infants were categorized into Category A, B or C according to the guidelines issued by the Ministry of Health and Family Welfare, India on influenza.</p><h3> Results</h3><p>The groups were comparable with respect to baseline characteristics. Greater number of women received influenza vaccine during the 1<sup>st</sup> trimester (n=117). During the gestation period, majority of the women in the vaccinated group were symptom free compared to the unvaccinated (92% vs 70.7%). Also, none of the vaccinated women were categorized into category C compared to one who was laboratory tested positive for influenza in the unvaccinated group. Similar results were seen postpartum and more number of infants remained symptoms free in the vaccinated group compared with unvaccinated (69.3% vs 25.9%). More number of infants were born pre‐term in the unvaccinated group compared to vaccinated (15.5% vs 8.6%). </p><h3> Conclusions</h3><p>Immunization with influenza vaccine in any trimester during pregnancy was found to protect the mother and infants upto 6 months of age against seasonal influenza without significant maternal adverse effects. In order to improve vaccination rates, there must be a national vaccination policy and incorporation of maternal immunisation in standard antenatal care.</p><p>This article is protected by copyright. All rights reserved.</p><h3> Background</h3><p>Influenza is a highly contagious disease with global annual outbreaks of 3–5 million severe cases and 0.25 to 0.5 million deaths. The risk is greater in pregnant women that results in high morbidity and mortality.</p><h3> Objective</h3><p>The objective of this study was to see the efficacy of influenza vaccine on pregnant women and their newborn upto six months.</p><h3> Method</h3><p>This was a retrospective study (January 2016–March 2018). Records of 346 pregnant women were included in this study (vaccinated: 288; unvaccinated: 58). Women and infants were categorized into Category A, B or C according to the guidelines issued by the Ministry of Health and Family Welfare, India on influenza.</p><h3> Results</h3><p>The groups were comparable with respect to baseline characteristics. Greater number of women received influenza vaccine during the 1<sup>st</sup> trimester (n=117). During the gestation period, majority of the women in the vaccinated group were symptom free compared to the unvaccinated (92% vs 70.7%). Also, none of the vaccinated women were categorized into category C compared to one who was laboratory tested positive for influenza in the unvaccinated group. Similar results were seen postpartum and more number of infants remained symptoms free in the vaccinated group compared with unvaccinated (69.3% vs 25.9%). More number of infants were born pre‐term in the unvaccinated group compared to vaccinated (15.5% vs 8.6%). </p><h3> Conclusions</h3><p>Immunization with influenza vaccine in any trimester during pregnancy was found to protect the mother and infants upto 6 months of age against seasonal influenza without significant maternal adverse effects. In order to improve vaccination rates, there must be a national vaccination policy and incorporation of maternal immunisation in standard antenatal care.</p><p>This article is protected by copyright. All rights reserved.</p>

Safety of the Seasonal Influenza Vaccine in 2 Successive Pregnancies

Safety of SARS-CoV-2 vaccination during pregnancy- obstetric outcomes from a large cohort study

Effectiveness of Influenza Vaccination During Pregnancy Against Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada

Association Between Influenza Vaccination and SARS‐CoV‐2 Infection

One “misunderstood” health issue: demonstrating and communicating the safety of influenza a vaccination in pregnancy: a systematic review and meta-analysis

Influenza vaccine: A viable option to protect pregnant women and infants from seasonal flu: A retrospective hospital‐based study in India

Associations of COVID-19 vaccination during pregnancy with adverse neonatal and maternal outcomes: A systematic review and meta-analysis

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022

COVID-19 Vaccine Safety in Pregnancy, A Nested Case-Control Study in Births From April 2021 to March 2022, England

Prenatal maternal inactivated COVID-19 vaccination: the maternal and neonatal outcomes, a retrospective cohort study

Risk of severe influenza infection in women with a history of pregnancy complications: A longitudinal cohort study

Prenatal Influenza Vaccination or Influenza Infection and Autism Spectrum Disorder in Offspring

COVID-19 diagnosis, vaccination during pregnancy, and adverse pregnancy outcomes of 865,654 women in England and Wales: a population-based cohort study

Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes

Pregnancy and severe influenza infection in the 2013-2014 influenza season

Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes

Safety and Protective Effects of Influenza Vaccination in Pregnant Women on Pregnancy and Birth Outcomes in Pune, India: A Cross-Sectional Study

Evaluating COVID-19 vaccine effectiveness during pre-Delta, Delta and Omicron dominant periods among pregnant people in the U.S.: Retrospective cohort analysis from a nationally sampled cohort in National COVID Collaborative Cohort (N3C)

Pregnancy Outcomes among Pregnant Persons after COVID-19 Vaccination: Assessing Vaccine Safety in Retrospective Cohort Analysis of U.S. National COVID Cohort Collaborative (N3C)

Maternal and neonatal safety of COVID‐19 vaccination during peri‐pregnancy period: a prospective study

Association of maternal infection of SARS-CoV-2 and neonatal susceptibility: A retrospective cohort study